Author

S. Lambing

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:ATAC-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

E. Bartok· 2 shared G. Hartmann· 2 shared M. Schlee· 2 shared A. Buness· 1 shared C. Hagen· 1 shared E. Hartmann· 1 shared F. Khan· 1 shared J. G. van den Boorn· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

E. Bartok

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

RIG-I activation primes and trains innate antiviral immune memory

M. S. Adamson, S. Nesic, A. Buness, K. Bayrak, S. Schmitz, S. Soler, T. Zillinger, S. Marx, S. Lambing, K. Andryka-Cegielski, F. Khan, T. M. Schlee-Guimaraes, S. Herberhold, M. Proietti, K. Placek, , E. Bartok

RIG-I activation primes and trains innate immune responses, enhancing non-specific antiviral protection in immune and non-immune cells.

bioRxiv · Oct 27, 2022 · PreprintImmunology

RIG-I immunotherapy overcomes radioresistance in p53-positive malignant melanoma

S. Lambing, S. Holdenrieder, P. Müller, Y. P. Tan, C. Hagen, S. Garbe, M. Schlee, J. G. van den Boorn, E. Bartok, G. Hartmann, M. Renn

This study shows that RIG-I ligands enhance radiation-induced tumor cell death and immunogenicity in melanoma, with p53 playing a key role in the synergy between RIG-I and radiation.

bioRxiv · Oct 16, 2021Immunology